Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1KK | ISIN: US23282W6057 | Ticker-Symbol: KK3A
Tradegate
27.06.25 | 20:02
28,400 Euro
0,00 % 0,000
1-Jahres-Chart
CYTOKINETICS INC Chart 1 Jahr
5-Tage-Chart
CYTOKINETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
28,40029,00011:05
28,00028,60027.06.

Aktuelle News zur CYTOKINETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)103SOUTH SAN FRANCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2025 it granted stock options to purchase an aggregate of...
► Artikel lesen
CYTOKINETICS Aktie jetzt für 0€ handeln
12.06.Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan4
10.06.Cytokinetics Calls for Donations3
10.06.Cytokinetics, Incorporated: Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program2
04.06.Cytokinetics auf der Jefferies-Konferenz: Marktexpansion für Aficamten22
29.05.Mizuho senkt Kursziel für Cytokinetics-Aktie von 103 auf 84 US-Dollar5
29.05.Mizuho cuts Cytokinetics stock target to $84 from $1031
27.05.Stifel maintains Buy rating and $87 target on Cytokinetics stock1
18.05.Cytokinetics, Incorporated: Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress5
16.05.Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)150SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40...
► Artikel lesen
15.05.Cytokinetics shares positive phase 3 results for aficamten in heart disease8
15.05.Cytokinetics, Incorporated: Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology1
13.05.Stifel maintains confidence in Cytokinetics stock post-trial success1
13.05.Cytokinetics rises as lead drug succeeds in late-stage trial4
13.05.Cytokinetics, Incorporated: Cytokinetics Announces Positive Topline Results From MAPLE-HCM346Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif....
► Artikel lesen
07.05.Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended6
07.05.Cytokinetics stock price target cut to $60 by Evercore ISI2
07.05.Cytokinetics shares hold as JMP reiterates $78 price target1
07.05.Cytokinetics targets aficamten approval with extended PDUFA timeline and growing clinical data5
06.05.CYTOKINETICS INC - 10-Q, Quarterly Report2
Weiter >>
103 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1